Modeling stroke in mice - middle cerebral artery occlusion with the filament model.
Stroke is among the most frequent causes of death and adult disability, especially in highly developed countries. However, treatment options to date are very limited. To meet the need for novel therapeutic approaches, experimental stroke research frequently employs rodent models of focal cerebral ischaemia. Most researchers use permanent or transient occlusion of the middle cerebral artery (MCA) in mice or rats. Proximal occlusion of the middle cerebral artery (MCA) via the intraluminal suture technique (so called filament or suture model) is probably the most frequently used model in experimental stroke research. The intraluminal MCAO model offers the advantage of inducing reproducible transient or permanent ischaemia of the MCA territory in a relatively non-invasive manner. Intraluminal approaches interrupt the blood flow of the entire territory of this artery. Filament occlusion thus arrests flow proximal to the lenticulo-striate arteries, which supply the basal ganglia. Filament occlusion of the MCA results in reproducible lesions in the cortex and striatum and can be either permanent or transient. In contrast, models inducing distal (to the branching of the lenticulo-striate arteries) MCA occlusion typically spare the striatum and primarily involve the neocortex. In addition these models do require craniectomy. In the model demonstrated in this article, a silicon coated filament is introduced into the common carotid artery and advanced along the internal carotid artery into the Circle of Willis, where it blocks the origin of the middle cerebral artery. In patients, occlusions of the middle cerebral artery are among the most common causes of ischaemic stroke. Since varying ischemic intervals can be chosen freely in this model depending on the time point of reperfusion, ischaemic lesions with varying degrees of severity can be produced. Reperfusion by removal of the occluding filament at least partially models the restoration of blood flow after spontaneous or therapeutic (tPA) lysis of a thromboembolic clot in humans. In this video we will present the basic technique as well as the major pitfalls and confounders which may limit the predictive value of this model.
Department for Experimental Neurology, Center for Stroke Research Berlin, Charit&eacute; Universit&auml;tsmedizin.
Odilo
O
Engel
Sabine
S
Kolodziej
Ulrich
U
Dirnagl
Vincent
V
Prinz
D000818:Animals; D002545:Brain Ischemia; D004195:Disease Models, Animal; D020244:Infarction, Middle Cerebral Artery / Q000209:etiology*; D051379:Mice; D020768:Middle Cerebral Artery / Q000601:surgery*; D012825:Silicon
D012825:Silicon
Stroke. 2009 Aug;40(8):2849-58
19443795
Magn Reson Med. 2000 Aug;44(2):252-8
10918324
Infect Disord Drug Targets. 2010 Apr;10(2):98-104
20166971
Neurosci Lett. 2003 Oct 2;349(2):130-2
12946569
Stroke. 2004 Jul;35(7):1720-5
15155973
J Neurosci Methods. 2002 Apr 15;115(2):169-79
11992668
Brain Pathol. 2003 Oct;13(4):452-64
14655751
Neurosci Lett. 2008 Jun 20;438(2):180-5
18456407
J Cereb Blood Flow Metab. 1993 Jul;13(4):683-92
8314921
Trends Neurosci. 1999 Sep;22(9):391-7
10441299
Eur J Neurosci. 2006 Apr;23(7):1757-65
16623832
J Neurosci Methods. 2009 Oct 30;184(1):95-103
19660497
Neuroreport. 2002 Aug 7;13(11):1431-5
12167768
J Neurosci Methods. 1997 Apr 25;73(1):45-8
9130677
Brain Res Mol Brain Res. 1999 Mar 5;65(2):135-42
10064884
Brain Res Bull. 2001 Jan 15;54(2):243-50
11275415
Nat Rev Neurosci. 2005 Oct;6(10):775-86
16163382
Stroke. 1989 Jan;20(1):84-91
2643202
Stroke. 1986 May-Jun;17(3):472-6
3715945
J Neurosci Methods. 1984 May;11(1):47-60
6471907
J Cereb Blood Flow Metab. 2008 Dec;28(12):1936-50
18628778
J Neurosci Methods. 2000 Dec 15;104(1):99-109
11163416
Stroke. 2008 May;39(5):1548-55
18340095
J Cereb Blood Flow Metab. 2006 Dec;26(12):1465-78
16525413
Circ Res. 2006 Nov 10;99(10):1132-40
17038638
J Neurosci Methods. 1991 Feb;36(2-3):219-28
2062117
Stroke. 1999 Dec;30(12):2752-8
10583007
Stroke. 2009 Mar;40(3):e50-2
18703798
J Cereb Blood Flow Metab. 1989 Oct;9(5):589-96
2674168
Nat Methods. 2009 Apr;6(4):257-61
19333241
J Pharm Pharmacol. 1968 Apr;20(4):302-4
4384609
J Neurosci Methods. 2006 May 15;153(1):104-13
16309746
Ann Neurol. 2003 Nov;54(5):582-90
14595647
Brain Res. 2003 Apr 25;970(1-2):131-9
12706254
Exp Neurol. 2007 Feb;203(2):555-67
17067578
J Neurosci Methods. 2008 Sep 15;174(1):18-24
18640153
J Exp Stroke Transl Med. 2009 Jan 1;2(2):2-27
20369026